The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; none of the 18 sources its claims cite is checked for support yet.
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Open accessPublished version of a preprint
Abstract
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1. Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature2–5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6. We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues. Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 10 Not checked yet · 7 Own method · 3 Own interpretation · 2 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, even for our middle-aged study population, practicing clinicians could not identify the 8% of individuals at ≥3-fold risk based on GPSCAD in the absence of genotype information (Supplementary Table 8).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.5% of the population at ≥3-fold risk and the top 1% had 3.30-fold risk. (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 6.1% of the population at ≥3-fold risk and the top 1% had 4.63-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.2% of the population at ≥3-fold risk and the top 1% had 3.87-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This predictor performed equivalently well in the testing dataset, with AUC of 0.81.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plainn = 288,978- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results for CAD generalized to four other diseases: risk increased sharply in the right tail of the GPS distribution (Figure 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our testing dataset, 19.8% of participants were at ≥3-fold increased risk for at least one of the five diseases studied (Table 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“GPSCAD performed substantially better than two previously published polygenic scores for coronary artery disease that included 50 and 49,310 variants, respectively (Supplementary Table 7 and Supplementary Fig. 1).17,18”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [17] Tada, H. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur. Heart J. 37, 561–567 (2016). source
- Not checked yetcites [18] Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The predictors had AUC ranging from 0.79 – 0.81 in the validation set, with the best predictor (GPSCAD) involving 6,630,150 variants (Supplementary Table 1).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelationaln = 120,280- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Across the population, GPSCAD is normally distributed with the empirical risk of CAD rising sharply in the right tail of the distribution, from 0.8% in the lowest percentile to 11.1% in the highest percentile (Figure 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In order to analyze individuals with a relatively homogenous ancestry and owing to small percentages of non-British individuals, the present analysis was restricted to the white British ancestry individuals.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Whereas identifying carriers of rare monogenic mutations requires sequencing of specific genes and careful interpretation of the functional effects of mutations found, polygenic scores can be readily calculated for many diseases simultaneously, based on data from a single genotyping array.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our validation and testing was performed in the UK Biobank population.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These initial efforts were hampered by three challenges: (i) the small size of initial genome-wide association studies (GWAS), which affected the precision of the estimated impact of individual variants on disease risk; (ii) limited computational methods for creating GPS; and (iii) lack of large datasets needed to validate and test GPS.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results above show that, for a number of common diseases, polygenic risk scores can now identify a substantially larger fraction of the population than found by rare monogenic mutations, at comparable or greater disease risk.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The vast majority of common disease occurs in individuals without rare monogenic mutations.
In the paper
“Individuals who volunteered for the UK Biobank tended to be more healthy than the general population;27”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [27] Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In both cases, it is important to recognize that the risk associated with a high polygenic score may not reflect a single underlying mechanism, but rather the combined influence of multiple pathways.28”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [28] Khera, A. V. & Kathiresan, S. Is coronary atherosclerosis one disease or many? Setting realistic expectations for precision medicine. Circulation 135, 1005–1007 (2017). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, we previously showed that a high polygenic risk for CAD may be offset by either of two interventions: adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications.19–21”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [19] Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016). source
- Not checked yetcites [20] Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264–2271 (2015). source
- Not checked yetcites [21] Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017). source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“UK Biobank samples were not included in any of the five discovery GWAS studies.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Polygenic score derivation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“An important example is the presence of a familial hypercholesterolemia mutation in 0.4% of the population, which confers an up to 3-fold increased risk for coronary artery disease (CAD).6”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [6] Abul-Husn, N. S. et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 354, pii: aaf7000 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Another example is the p.E508K missense mutation in HNF1A, with carrier frequency of 0.1% of the general population and 0.7% of Latinos,8 which confers up to 5-fold increased risk for type 2 diabetes.9”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [8] Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). source
- Not checked yetcites [9] Estrada, K. et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311, 2305–2314 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The vast majority of common disease occurs in individuals without rare monogenic mutations.
“Although ascertainment of monogenic mutations can be highly relevant for carriers and their families, the vast majority of disease occurs in those without such mutations.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, integrated models of PRS together with other lifestyle and clinical factors have enabled clinicians to more accurately quantify the risk of heart attack for patients;”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This enthusiasm is driven by observations that a polygenic burden of LDL-increasing SNPs can confer monogenic-equivalent risk of cardiovascular disease, with polygenic scores improving clinical models for risk assessment and statin prescription that can reduce coronary heart disease and improve healthcare delivery efficiency5–7.”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using polygenic scores, it is now possible to combine information from millions of genomic variants to identify people whose overall polygenic risk of coronary artery disease is as high as that of patients with monogenic lipid disorders such as familial hypercholesterolemia [23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, they have contributed new approaches to risk prediction for adverse phenotypes related to heart disease [21–23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
In the citing paper
“As described below, findings from GWAS have increasing translational impact through identification of novel therapeutic targets67, prioritization (and deprioritization) of existing ones68 and development of polygenic scores that quantify individual genetic risk69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“The development of robust polygenic scores for several common diseases has been catalysed by more precise per-variant effect estimates from larger GWAS datasets, improved algorithms for combining information across millions of single-nucleotide polymorphisms, and large-scale biobanks that support score validation69,146,147.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“For example, a genome-wide polygenic score for heart attack, incorporating 6.6 million variants, indicates that 5% of European-descent individuals have a risk of future cardiac events equivalent to that seen in those with less frequent monogenic forms of hypercholesterolaemia69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“This paper used large-scale genetic data to demonstrate the clinical potential of the polygenic scores that can be constructed for many common diseases, emphasizing that, in some situations, the lifetime risk of disease for those with the highest scores approaches that of established monogenic disease.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Statistical analysis within the testing dataset
“For each disease, the GPS with the best discriminative capacity in the testing dataset was calculated in the testing dataset of 288,278 participants”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Self-citationCommon polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,006
Ding, Y., Hou, K., Burch, K. S., Lapinska, S., Privé, F., Vilhjálmsson, B. J., Sankararaman, S., & Paşaniuc, B. (2021) · Nature Genetics · doi:10.1038/s41588-021-00961-5 · Cited by 142
Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts
Cirulli, E. T., White, S., Read, R. W., Elhanan, G., Metcalf, W. J., Tanudjaja, F., Fath, D. M., Sandoval, E., Isaksson, M., Schlauch, K. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14288-y · Cited by 140
Aragam, K. G., Dobbyn, A. L., Judy, R., Chaffin, M. D., Chaudhary, K., Hindy, G., Cagan, A., Finneran, P., Weng, L.-C. C., Loos, R. J. F., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.027 · Cited by 137
Self-citationPolygenic risk scores and breast cancer risk prediction
Roberts, E., Howell, S. J., & Evans, D. G. (2023) · The Breast · doi:10.1016/j.breast.2023.01.003 · Cited by 135
Disease modification and biomarker development in Parkinson disease
Espay, A. J., Kalia, L. V., Gan‐Or, Z., Williams‐Gray, C. H., Bedard, P. L., Rowe, S. M., Morgante, F., Fasano, A. A., Stecher, B., Kauffman, M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009107 · Cited by 137
Zhang, Y., Hurson, A. N., Zhang, H., Choudhury, P. P., Easton, D. F., Milne, R. L., Simard, J., Hall, P. N., Michailidou, K., Dennis, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16483-3 · Cited by 134
Toward a fine-scale population health monitoring system
Belbin, G. M., Cullina, S., Wenric, S., Soper, E. R., Glicksberg, B. S., Torre, D., Moscati, A., Wojcik, G. L., Shemirani, R., Beckmann, N. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.034 · Cited by 136
Spritz, R. A., & Santorico, S. A. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.004 · Cited by 135
Validity of polygenic risk scores: are we measuring what we think we are?
Janssens, A. C. J. W. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz205 · Cited by 129
“A recent trend in the construction of PRSs is to use millions of SNPs in the prediction of risks (27,57,58).”
BackgroundMethodInfluentialThe advantages of UK Biobank's open‐access strategy for health research
Conroy, M. C., Sellors, J., Effingham, M., Littlejohns, T. J., Boultwood, C., Gillions, L., Sudlow, C. L. M., Collins, R., & Allen, N. E. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12955 · Cited by 130
Emdin, C. A., Haas, M., Ajmera, V. H., Simon, T. G., Homburger, J. R., Neben, C. L., Jiang, L., Wei, W., Feng, Q., Zhou, A. Y., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.011 · Cited by 131
Self-citationDennis, J. K., Sealock, J., Straub, P., Lee, Y. A., Hucks, D., Actkins, K. V., Faucon, A. B., Feng, Y. A., Ge, T., Goleva, S. B., et al. (2021) · Genome Medicine · doi:10.1186/s13073-020-00820-8 · Cited by 132
A practical view of fine-mapping and gene prioritization in the post-genome-wide association era
Broekema, R., Bakker, O. B., & Jonkers, I. H. (2020) · Open Biology · doi:10.1098/rsob.190221 · Cited by 141
PRSet: Pathway-based polygenic risk score analyses and software
Choi, S. W., García‐González, J., Ruan, Y., Wu, H. M., Porras, C., Johnson, J., Hoggart, C. J., & O’Reilly, P. F. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010624 · Cited by 133
Self-citationLiu, G., Peng, J., Liao, Z., Locascio, J. J., Corvol, J.-C., Zhu, F., Dong, X., Maple-Grødem, J., Campbell, M. C., Elbaz, A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00847-6 · Cited by 127
Trinder, M., Walley, K. R., Boyd, J. H., & Brunham, L. R. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313381 · Cited by 126
Polygenic risk scores: a biased prediction?
Vega, F. M. D. L., & Bustamante, C. D. (2018) · Genome Medicine · doi:10.1186/s13073-018-0610-x · Cited by 132
Single-cell genomics meets human genetics
Cuomo, A. S. E., Nathan, A., Raychaudhuri, S., MacArthur, D. G., & Powell, J. E. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00599-5 · Cited by 124
The Genetic Basis of Metabolic Disease
Barroso, I., & McCarthy, M. I. (2019) · Cell · doi:10.1016/j.cell.2019.02.024 · Cited by 129
Monogenic and Polygenic Contributions to Atrial Fibrillation Risk
Choi, S. H., Jurgens, S. J., Weng, L.-C. C., Pirruccello, J. P., Roselli, C., Chaffin, M. D., Lee, C. J., Hall, A. W., Khera, A. V., Lunetta, K. L., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315686 · Cited by 129
Self-citationMoll, M. R., Sakornsakolpat, P., Shrine, N. R. G., Hobbs, B. D., DeMeo, D. L., John, C., Guyatt, A. L., McGeachie, M. J., Gharib, S. A., Obeidat, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30101-6 · Cited by 130
Returning integrated genomic risk and clinical recommendations: The eMERGE study
Linder, J. E., Allworth, A., Bland, H. T., Caraballo, P. J., Chisholm, R. L., Clayton, E. W., Crosslin, D. R., Dikilitas, O., DiVietro, A., Esplin, E. D., et al. (2023) · Genetics in Medicine · doi:10.1016/j.gim.2023.100006 · Cited by 125
Demographic history mediates the effect of stratification on polygenic scores
Zaidi, A. A., & Mathieson, I. (2020) · eLife · doi:10.7554/elife.61548 · Cited by 122
Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank
Jacobs, B. M., Belete, D., Bestwick, J. P., Blauwendraat, C., Bandrés‐Ciga, S., Heilbron, K., Dobson, R., Nalls, M. A., Singleton, A., Hardy, J., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323646 · Cited by 126
Suárez, L. J., Garzon, H. S., Arboleda, S., & Rodríguez, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591255 · Cited by 122
Collin, C. B., Gebhardt, T., Golebiewski, M., Karaderi, T., Hillemanns, M., Khan, F. M., Salehzadeh‐Yazdi, A., Kirschner, M. W., Krobitsch, S., & Kuepfer, L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020166 · Cited by 128
Zhang, J., Fang, X., Wu, J., Fan, Y., Leng, R., Liu, B., Lv, X.-J., Yan, Y.-L., Mao, C., & Ye, D. (2023) · Environmental Health Perspectives · doi:10.1289/ehp10710 · Cited by 124
Homburger, J. R., Neben, C. L., Mishne, G., Zhou, A. Y., Kathiresan, S., & Khera, A. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0682-2 · Cited by 125
Self-citationFinnGen, Sakaue, S., Kanai, M., Karjalainen, J. M., Akiyama, M., Kurki, M., Matoba, N., Takahashi, A., Hirata, M., Kubo, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0785-8 · Cited by 121
Circulating Protein Signatures and Causal Candidates for Type 2 Diabetes
Guðmundsdóttir, V., Zaghlool, S. B., Emilsson, V., Aspelund, T., Ilkov, M., Gudmundsson, E. F., Jonsson, S. M., Zilhäo, N. R., Lamb, J. R., Suhre, K., et al. (2020) · Diabetes · doi:10.2337/db19-1070 · Cited by 121
Moingeon, P. E., Kuenemann, M. A., & Guedj, M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.006 · Cited by 122
Linz, D., Andrade, J. G., Arbelo, E., Boriani, G., BREITHARDT, G. E., Camm, A. J., Caso, V., Nielsen, J. C., Melis, M. D., Potter, T. J. R. D., et al. (2024) · EP Europace · doi:10.1093/europace/euae070 · Cited by 124
Polygenic Scores for Height in Admixed Populations
Bitarello, B. D., & Mathieson, I. (2020) · G3 Genes Genomes Genetics · doi:10.1534/g3.120.401658 · Cited by 122
Khan, S. S., Post, W. S., Guo, X., Tan, J., Zhu, F., Bos, D., Sedaghati-Khayat, B., van Rooij, J., Aday, A., Allen, N. B., et al. (2023) · JAMA · doi:10.1001/jama.2023.7575 · Cited by 117
Cardiovascular Precision Medicine in the Genomics Era
Dainis, A., & Ashley, E. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.003 · Cited by 119
Adeyemo, A., Zaghloul, N. A., Chen, G., Doumatey, A. P., Leitch, C. C., Hostelley, T. L., Nesmith, J. E., Zhou, J., Bentley, A. R., Shriner, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10967-7 · Cited by 117
Finer, S., Martin, H. C., Khan, A., Hunt, K. A., MacLaughlin, B., Ahmed, Z., Ashcroft, R. E., Durham, C., MacArthur, D. G., McCarthy, M. I., et al. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz174 · Cited by 119
Ye, Y., Chen, X. D., Han, J. J., Jiang, W., Natarajan, P., & Zhao, H. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003128 · Cited by 119
Self-citationQuantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders
Oetjens, M. T., Kelly, M., Sturm, A. C., Martin, C. L., & Ledbetter, D. H. (2019) · Nature Communications · doi:10.1038/s41467-019-12869-0 · Cited by 120
Rahimi, Y., Bihamta, M. R., Taleei, A., Alipour, H., & Ingvarsson, P. K. (2019) · BMC Plant Biology · doi:10.1186/s12870-019-2165-4 · Cited by 114
Implementation and implications for polygenic risk scores in healthcare
Slunecka, J. L., van der Zee, M. D., Beck, J. J., Johnson, B. N., Finnicum, C. T., Pool, R., Hottenga, J., de Geus, E. J. C., & Ehli, E. A. (2021) · Human Genomics · doi:10.1186/s40246-021-00339-y · Cited by 120
Hindley, G., Frei, O., Shadrin, A. A., Cheng, W., O’Connell, K. S., Icick, R., Parker, N., Bahrami, S., Karadag, N., Roelfs, D., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21101051 · Cited by 119
Complex Trait Prediction from Genome Data: Contrasting EBV in Livestock to PRS in Humans
Wray, N. R., Kemper, K. E., Hayes, B. J., Goddard, M. E., & Visscher, P. M. (2019) · Genetics · doi:10.1534/genetics.119.301859 · Cited by 113
Can Genetic Testing Identify Talent for Sport?
Pickering, C., Kiely, J., Grgić, J., Lucía, A., & Coso, J. D. (2019) · Genes · doi:10.3390/genes10120972 · Cited by 119
Molecular Genetics and Complex Inheritance of Congenital Heart Disease
Diab, N. S., Barish, S., Dong, W., Zhao, S., Allington, G., Yu, X., Kahle, K. T., Brueckner, M. K., & Jin, S. C. (2021) · Genes · doi:10.3390/genes12071020 · Cited by 114
Genetic Risk for Overall Cancer and the Benefit of Adherence to a Healthy Lifestyle
Zhu, M., Wang, T., Huang, Y., Zhao, X., Ding, Y., Zhu, M., Ji, M., Wang, C., Dai, J., Yin, R. H., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0836 · Cited by 114
Genetics of Type 2 Diabetes: Implications from Large-Scale Studies
DeForest, N., & Majithia, A. R. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01462-3 · Cited by 112
Hindy, G., Aragam, K. G., Ng, K., Chaffin, M. D., Lotta, L. A., Baras, A., Drake, I., Orho‐Melander, M., Melander, O., Kathiresan, S., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314856 · Cited by 112
Self-citationThe translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 116
Genotyping, sequencing and analysis of 140,000 adults from Mexico City
Ziyatdinov, A., Torres, J., Alegre-Díaz, J., Backman, J., Mbatchou, J. S., Turner, M., Gaynor, S. M., Joseph, T., Zou, Y., Liu, D., et al. (2023) · Nature · doi:10.1038/s41586-023-06595-3 · Cited by 117
Screening Human Embryos for Polygenic Traits Has Limited Utility
Karavani, E., Zuk, O., Zeevi, D., Barzilai, N., Stefanis, N. C., Hatzimanolis, A., Smyrnis, N., Avramopoulos, D., Kruglyak, L., Atzmon, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.033 · Cited by 111
Schizophrenia polygenic risk score and 20-year course of illness in psychotic disorders
Jonas, K. G., Lencz, T., Li, K., Malhotra, A. K., Perlman, G., Fochtmann, L. J., Bromet, E. J., & Kotov, R. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0612-5 · Cited by 117
Leveraging base-pair mammalian constraint to understand genetic variation and human disease
Sullivan, P. F., Meadows, J. R. S., Gazal, S., Phan, B. N., Li, X., Genereux, D. P., Dong, M. X., Bianchi, M., Andrews, G., Sakthikumar, S., et al. (2023) · Science · doi:10.1126/science.abn2937 · Cited by 113
Human Disease Variation in the Light of Population Genomics
Prohaska, A., Racimo, F., Schork, A. J., Sikora, M., Stern, A. J., Ilardo, M. A., Allentoft, M. E., Folkersen, L., Buil, A., Moreno-Mayar, J. V., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.052 · Cited by 110
Geographic Variation and Bias in the Polygenic Scores of Complex Diseases and Traits in Finland
Kerminen, S., Martin, A. R., Koskela, J. T., Ruotsalainen, S., Havulinna, A. S., Surakka, I. L., Palotie, A. V., Perola, M., Salomaa, V. V., Daly, M. J., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.05.001 · Cited by 111
The impact of age on genetic risk for common diseases
Jiang, X., Holmes, C. C., & McVean, G. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009723 · Cited by 110
The Opioid Crisis and the Future of Addiction and Pain Therapeutics
Coussens, N. P., Sittampalam, G. S., Jonson, S. G., Hall, M. D., Gorby, H. E., Tamiz, A. P., McManus, O. B., Felder, C. C., & Rasmussen, K. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.259408 · Cited by 112
United Kingdom Biobank (UK Biobank)
Caleyachetty, R., Littlejohns, T. J., Lacey, B., Bešević, J., Conroy, M. C., Collins, R., & Allen, N. E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.342 · Cited by 107
Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
Stoekenbroek, R. M., Kallend, D. G., Wijngaard, P. L. J., & Kastelein, J. J. P. (2018) · Future Cardiology · doi:10.2217/fca-2018-0067 · Cited by 106
Is population structure in the genetic biobank era irrelevant, a challenge, or an opportunity?
Lawson, D. J., Davies, N. M., Haworth, S. J., Ashraf, B. H., Howe, L. J., Crawford, A. A., Hemani, G., Smith, G. D., & Timpson, N. J. (2019) · Human Genetics · doi:10.1007/s00439-019-02014-8 · Cited by 106
Genetics of Atopic Dermatitis: From DNA Sequence to Clinical Relevance
Løset, M., Brown, S., Saunes, M., & Hveem, K. (2019) · Dermatology · doi:10.1159/000500402 · Cited by 110
Family health history: underused for actionable risk assessment
Ginsburg, G. S., Wu, R. R., & Orlando, L. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31275-9 · Cited by 105
Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences
Rosenberg, N. A., Edge, M. D., Pritchard, J. K., & Feldman, M. W. (2019) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoy036 · Cited by 105
Genetics of coronary artery disease in the post‐GWAS era
Chen, Z., & Schunkert, H. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13362 · Cited by 111
Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
Kessler, T., & Schunkert, H. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.001 · Cited by 111
Disease risk scores for skin cancers
Fontanillas, P., Alipanahi, B., Furlotte, N. A., Johnson, M., Wilson, C. H., Agee, M., Bell, R. K., Bryc, K., Elson, S. L., Hinds, D. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20246-5 · Cited by 105
Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity
Chen, L., Wang, Y., Liu, L., Bielowka, A. M., Ahmed, R., Zhang, H., Tombleson, P., Roberts, A. L., Odhams, C. A., Graham, D. S. C., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa030 · Cited by 105
Electronic health records and polygenic risk scores for predicting disease risk
Li, R., Chen, Y., Ritchie, M. D., & Moore, J. H. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0224-1 · Cited by 106
Zhu, Z., Hasegawa, K., Camargo, C. A., & Liang, L. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.004 · Cited by 105
Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians
Wang, M., Menon, R., Mishra, S., Patel, A. P., Chaffin, M. D., Tanneeru, D., Deshmukh, M., Mathew, O., Apte, S., Devanboo, C. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.024 · Cited by 106
Self-citationGenomics and psychological resilience: a research agenda
Choi, K. W., Stein, M. B., Dunn, E. C., Koenen, K. C., & Smoller, J. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0457-6 · Cited by 108
Shah, R. A., Asatryan, B., Dabbagh, G. S., Aung, N., Khanji, M. Y., Lopes, L. R., van Duijvenboden, S., Holmes, A. M., Muser, D., Landstrom, A. P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058143 · Cited by 103
Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease
Schunkert, H., Angelantonio, E. D., Inouye, M., Patel, R. S., Ripatti, S., Widén, E., Sanderson, S. C., Kaski, J. P., McEvoy, J. W., Vardas, P. E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae649 · Cited by 107
Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families
Gormley, P., Kurki, M., Hiekkala, M. E., Veerapen, K., Häppölä, P., Mitchell, A. A., Lal, D., Palta, P., Surakka, I. L., Kaunisto, M. A., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.04.014 · Cited by 102
On the utilization of polygenic risk scores for therapeutic targeting
Gibson, G. C. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008060 · Cited by 102
Genetic Studies of Inflammatory Bowel Disease-Focusing on Asian Patients
Park, S. C., & Jeen, Y. T. (2019) · Cells · doi:10.3390/cells8050404 · Cited by 101
Genetics of common cerebral small vessel disease
Bordes, C., Sargurupremraj, M., Mishra, A., & Debette, S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00592-8 · Cited by 108
A new method for multiancestry polygenic prediction improves performance across diverse populations
Zhang, H., Zhan, J., Jin, J., Zhang, J., Lu, W., Zhao, R., Ahearn, T. U., Yu, Z., O’Connell, J., Jiang, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01501-z · Cited by 116
Fernainy, P., Cohen, A. A., Murray, E. J., Losina, E., Lamontagne, F., & Sourial, N. (2024) · BMC Proceedings · doi:10.1186/s12919-023-00285-8 · Cited by 112
The Genetics of Neuropathic Pain from Model Organisms to Clinical Application
Calvo, M., Davies, A. J., Hébert, H. L., Weir, G. A., Chesler, E. J., Finnerup, N. B., Levitt, R. C., Smith, B. H., Neely, G. G., Costigan, M., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.018 · Cited by 105
The genetic etiology of eosinophilic esophagitis
Kottyan, L. C., Parameswaran, S., Weirauch, M. T., Rothenberg, M. E., & Martin, L. J. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.013 · Cited by 100
Revealing the role of the human blood plasma proteome in obesity using genetic drivers
Zaghlool, S. B., Sharma, S., Molnar, M., Matías‐García, P. R., Elhadad, M. A., Waldenberger, M., Peters, A., Rathmann, W., Graumann, J., Gieger, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21542-4 · Cited by 106
Cai, M., Xiao, J., Zhang, S., Wan, X., Zhao, H., Chen, G., & Yang, C. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.03.002 · Cited by 102
Goodrich, J. K., Singer‐Berk, M., Son, R. G., Sveden, A., Wood, J. C., England, E. M., Cole, J. B., Weisburd, B., Watts, N., Caulkins, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23556-4 · Cited by 104
Opportunities and Challenges for Molecular Understanding of Ciliopathies–The 100,000 Genomes Project
Wheway, G., Genomics England Research Consortium, & Mitchison, H. M. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00127 · Cited by 99
How precision medicine and screening with big data could increase overdiagnosis
Vogt, H., Green, S., Ekstrøm, C. T., & Brodersen, J. (2019) · BMJ · doi:10.1136/bmj.l5270 · Cited by 103
Palk, A. C., Dalvie, S., de Vries, J., Martin, A. R., & Stein, D. J. (2019) · Philosophy Ethics and Humanities in Medicine · doi:10.1186/s13010-019-0073-8 · Cited by 98
Space is the Place: Effects of Continuous Spatial Structure on Analysis of Population Genetic Data
Battey, C. J., Ralph, P. L., & Kern, A. D. (2020) · Genetics · doi:10.1534/genetics.120.303143 · Cited by 99
Johansson, Å., Andreassen, O. A., Brunak, S., Franks, P. W., Hedman, H., Loos, R. J. F., Meder, B., Melén, E., Wheelock, C. E., & Jacobsson, B. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13640 · Cited by 102
Genetics of ADHD: What Should the Clinician Know?
Grimm, O., Kranz, T. M., & Reif, A. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-1141-x · Cited by 97
Page, G. P., Kanias, T., Guo, Y., Lanteri, M. C., Zhang, X., Mast, A. E., Cable, R. G., Spencer, B. R., Kiss, J. E., Fang, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146077 · Cited by 103
HIV-1 and human genetic variation
McLaren, P. J., & Fellay, J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00378-0 · Cited by 100
Genomic Predictors of Asthma Phenotypes and Treatment Response
Hernandez‐Pacheco, N., Pino-Yanes, M. D. M., & Flores, C. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00006 · Cited by 99
Opportunities, resources, and techniques for implementing genomics in clinical care
Manolio, T. A., Rowley, R. K., Williams, M. S., Roden, D. M., Ginsburg, G. S., Bult, C. J., Chisholm, R. L., Deverka, P. A., McLeod, H. L., Mensah, G. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31140-7 · Cited by 105
Characterizing the Genetic Architecture of Parkinson's Disease in Latinos
Loesch, D. P., Horimoto, A. R. V. R., Heilbron, K., Sarihan, E. I., Inca‐Martinez, M., Mason, E., Cornejo‐Olivas, M., Torres, L., Mazzetti, P., Cosentino, C., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26153 · Cited by 96
The Genetics of Inflammatory Bowel Disease
Hadad, J. E., Schreiner, P., Vavricka, S. R., & Greuter, T. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00678-7 · Cited by 96
Recent advances in polygenic scores: translation, equitability, methods and FAIR tools
Xiang, R., Kelemen, M., Xu, Y., Harris, L. W., Parkinson, H., Inouye, M., & Lambert, S. A. (2024) · Genome Medicine · doi:10.1186/s13073-024-01304-9 · Cited by 102
Nutrition Concepts for the Treatment of Obesity in Adults
Wiechert, M., & Holzapfel, C. (2021) · Nutrients · doi:10.3390/nu14010169 · Cited by 107
Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases
Ritchie, S. C., Lambert, S. A., Arnold, M., Teo, S. M., Lim, S. I., Šćepanović, P., Marten, J., Zahid, S., Chaffin, M. D., Liu, Y., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00478-5 · Cited by 96
Self-citationPersonalized Intervention Based on Early Detection of Atherosclerosis
Nielsen, R. V., Fuster, V., Bundgaard, H., Fuster, J. J., Johri, A. M., Kofoed, K. F., Douglas, P. S., Diederichsen, A. C. P., Shapiro, M. D., Nicholls, S. J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.053 · Cited by 98
Metadata
- Authors
- Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., & Kathiresan, S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Kathiresan, Sekar
- ORCID
- Venue
- Nature Genetics
- Published
- 2018-08-13
- Volume
- 50
- Issue
- 9
- Pages
- 1219-1224
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC6128408
- OpenAlex
- W2886752110
- Semantic Scholar
- d5eb49c11d070114e2ff46224099895c6b4b1558
- Cited by
- 2,953
- References
- 46
- Citations by year
- 2026: 276 · 2025: 290 · 2024: 363 · 2023: 362 · 2022: 433 · 2021: 411 · 2020: 451 · 2019: 307 · 2018: 57
- FWCI
- 189.86
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Doris Duke Charitable Foundation (2014105)
- Massachusetts General Hospital (HL007208)
- Harvard Catalyst (TR001100)
- Vertex Pharmaceuticals
- KR Foundation
- National Institutes of Health (KL2TR001100, HL0-07734, HL007208, T32-HL007734)
- National Heart, Lung, and Blood Institute (R01HL127564, HL007208, HL127564, R01HL128914, T-32HL007734, K08HL140203, HL007734, K23HL114724, K24HL105780, R01HL142711, R01HL092577, T32HL007208, R01HL139731)
- National Human Genome Research Institute (UM1HG008895)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and phenotypic traits in livestock
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- polygenic risk score, monogenic mutations, common diseases, coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, breast cancer, high-risk individuals, clinical risk stratification
- MeSH terms
- Adult, Aged, Disease, Female, Humans, Male, Middle Aged, Mutation, Risk Factors, Genetic Predisposition to Disease, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
